PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. (Nasdaq: PRDS) is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies, most notably its lead candidate PBI-0451 targeting SARS-CoV-2. The company went public through a merger with FS Development Corp. II, a blank-check company sponsored by Foresite Capital Management, with the SPAC having completed its IPO in 2021. The 8-K filing dated June 29, 2021 was submitted as part of the company's reporting obligations in connection with that transaction. Pardes operated in the healthcare and life sciences sector, concentrating on small-molecule antiviral drug discovery. Sign up on SpacDesk for full filing history, deal timelines, and sponsor data on Pardes Biosciences and hundreds of other SPAC transactions.